Abbott Laboratories Corporation

Tapas Das

Pradip Mukerji

Yung-Sheng Huang

Suzette Pereira

Jennifer M Thurmond

Amanda Eun-Yeong Leonard

Normanella Dewille

Gaurav Patel

Amanda E Leonard

Padmavathy Krishnan

Rockendra Gupta

Jennifer Parker-Barnes

Terrence B Mazer

Robert A Shalwitz

Chron-Si Lai

Paul W Johns

Terry Bruce Mazer

Mustafa Vurma

Megan Terp

Keith E Rushlow

Anand Seth

Allison Atnip

Suzette L Pereira

Normanella T Dewille

Liquid nutritional compositions have an off-white color with a Hunter L value not less than 68, and comprise (a) a protein; (b) a carbohydrate; (c) an oxidizable fish oil containing an omega-3 polyunsaturated fatty acid; (d) rosmarinic acid; and (e) ferric iron comprising ferric orthophosphate and/or ferric pyrophosphate. The liquid nutritional compositions exhibit reduced off-flavors and aromas typically encountered in compositions including fish oil.

Liquid nutritional compositions containing oxidizable fish oil, rosmarinic acid, and ferric iron

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Liquid nutritional compositions include functional ingredients such as beta-hydroxy-beta-methylbutyrate, docosahexaenoic acid, and lutein. The nutritional compositions are useful to promote at least one of physical performance (e.g., body composition, muscle mass, muscle strength) and cognitive function (e.g., focus, attention, alertness, executive function) in an individual. The functional ingredients are incorporated into the nutritional composition in such a way that they do not adversely affect the desirable properties of the nutritional composition such as, for example, nutritional value, stability, solubility, taste, and mouthfeel.

Reduced fat, shelf stable liquid nutritional composition

Liquid nutritional compositions that include functional ingredients such as beta-hydroxy-beta-methylbutyrate, docosahexaenoic acid, and lutein are disclosed. The nutritional compositions are useful to promote at least one of physical performance (e.g., body composition, muscle mass, muscle strength) and cognitive function (e.g., focus, attention, alertness, executive function) in an individual. The functional ingredients are incorporated into the nutritional composition in such a way that they do not adversely affect the desirable properties of the nutritional composition such as, for example, nutritional value, stability, solubility, taste, and mouthfeel.

Disclosed are antibodies that specifically recognize &#x394;5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The &#x394;5-desaturase-specific antibodies provide improved methods of detecting &#x394;5-desaturase in a sample.

Antibodies against delta-5 desaturase and uses thereof

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., '&#x394;9-elongase') and to uses thereof. In particular, &#x394;9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) is then catalyzed by &#x394;8-desaturase and &#x394;5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Elongase gene and uses thereof

Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 &#x3bc;g selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.

Compositions for improving breast health in women

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., '&#x394;5-desaturase') and at carbon 6 (i.e., '&#x394;6-desaturase') and to uses thereof. In particular, &#x394;5-desaturase may be utilized, for example, in the conversion of dihomo-&#x3b3;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &#x3b3;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;-6 desaturase and uses thereof

Desaturase genes and uses thereof

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 4 (i.e., '&#x394;4-desaturase'). In particular, &#x394;4-desaturase may be utilized, for example, in the conversion of adrenic acid to &#x3c9;6-docosapentaenoic acid and in the conversion of &#x3c9;3-docosapentaenoic acid to docosahexaenoic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;4-desaturase genes and uses thereof

The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., 'elongases') and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &#x3c9;6-docosapentaenoic acid or &#x3c9;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Growing community of inventors

Worthington, OH, United States of America

Tapas Das